证券代码：600998 证券简称：九州通 公告编号：临 2025-044 九州通医药集团股份有限公司 关于控股股东 2022 年非公开发行可交换公司债券 换股进展的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 依据募集说明书的相关约定，九州通医药集团股份有限公司（以下简称"公 司"）控股股东楚昌投资集团有限公司（以下简称"楚昌投资"）2022年非公开发 行的可交换公司债券（以下简称"可交债"）持有人于2024年12月19日至2025 年6月9日期间行使换股权利，导致楚昌投资的持股比例被动下降，不触及要约收 购。 ● 本次可交债换股不会导致公司控股股东及实际控制人发生变化。 ● 本次可交债换股后，楚昌投资及其一致行动人持有公司股权比例从 关约定，"楚昌投资集团有限公司2022年面向专业投资者非公开发行可交换公司 债券（第一期）"（以下简称"22楚EB01"）的持有人于2024年12月19日至2025 年6月9日期间行使换股权利，累计换股14,477,602股，导致公司控股股东楚昌投 资及其一致行 ...

Group 1 - The core announcement is about the exchange period of the convertible bonds issued by the controlling shareholder, Jinlong Energy, which will begin on June 3, 2025 [1][2] - The convertible bonds, named "24 Jinlong EB01," were issued on December 2, 2024, with a total scale of 1.15 billion yuan and a maturity of three years [1] - The initial conversion price for the bonds is set at 9.8 yuan per share, which may be adjusted due to the company's 2024 equity distribution [2] Group 2 - As of the announcement date, the actual controllers of the company hold a total of 1,954.12 million shares, accounting for 42.00% of the total share capital, with Jinlong Energy holding 913.18 million shares, or 19.63% [2] - The potential reduction in shares held by Jinlong Energy due to bondholders exercising their conversion rights is noted, but it is stated that this will not change the control of the company or significantly impact its governance structure [2][3] - The company will continue to monitor the conversion situation of the bonds and fulfill its information disclosure obligations as required by law [3]

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical-stage biopharmaceutical development, particularly focusing on its vitiligo drug candidate EB06, while reporting financial results that reflect a strategic pivot in operational activities towards this program [1][4]. Financial Overview - For the three months ended March 31, 2025, total operating expenses decreased by $0.6 million to $1.6 million compared to $2.2 million for the same period in 2024 [7] - The company reported a net loss of $1.6 million, or $0.30 per common share, for the quarter, an improvement from a net loss of $1.9 million, or $0.58 per common share, for the same quarter last year [8] - For the six months ended March 31, 2025, total operating expenses decreased by $0.6 million to $3.5 million compared to $4.1 million for the same period in 2024 [9] - The net loss for the six months was $3.2 million, or $0.74 per common share, compared to a net loss of $3.5 million, or $1.12 per common share, for the same period last year [11] Business Development - The company completed a $15 million equity financing to support the development of EB06, an anti-CXCL10 monoclonal antibody for vitiligo [2] - Edesa has initiated outreach to potential investigators and manufacturing activities to support U.S. regulatory approval for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients [2][6] - The planned Phase 2 study for EB06 is already approved in Canada, with drug manufacturing data expected to be submitted to the FDA in the second half of 2025 [6] Research and Development - Research and development expenses decreased by $0.7 million to $0.5 million for the three months ended March 31, 2025, primarily due to decreased external research expenses related to the investigational drug paridiprubart [9][16] - General and administrative expenses increased by $0.2 million to $1.2 million for the three months ended March 31, 2025, mainly due to increased salaries and related costs [9] Cash Position - As of March 31, 2025, Edesa had cash and cash equivalents of $13.9 million and working capital of $13.5 million [12]

Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases [1][3] - The company has a clinical pipeline targeting two therapeutic areas: Medical Dermatology and Respiratory [3] Medical Dermatology - Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate for treating vitiligo, an autoimmune disorder [3] - The company also has EB01 (1.0% daniluromer cream), which is Phase 3-ready for moderate-to-severe chronic Allergic Contact Dermatitis (ACD) [3] Respiratory - The most advanced respiratory drug candidate is EB05 (paridiprubart), currently evaluated in a U.S. government-funded study for Acute Respiratory Distress Syndrome [3] - EB05 has received two funding awards from the Government of Canada to support its development [3] - Edesa is preparing an investigational new drug application (IND) for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis [3] Upcoming Events - Edesa will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference on May 5-6, 2025, in Toronto [1][2] - Management is scheduled to present on May 5 at 4:00pm ET [2]

| 公司控股股东万泽集团有限公司保证向本公司提供的信息内容真实、准 | | --- | | 确、完整，没有虚假记载、误导性陈述或重大遗漏。 | | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 | | 虚假记载、误导性陈述或重大遗漏。 | 万泽实业股份有限公司（以下简称"公司"或"本公司"）的控股股东 万泽集团有限公司（以下简称"万泽集团"）2022 年面向专业投资者非公开 发行可交换公司债券（第一期）（债券简称：22 泽 EB01、22 泽 EB02）以本 公司股票为标的，于 2023 年 5 月 25 日进入换股期，换股期限为 2023 年 5 月 25 日起至 2025 年 11 月 21 日止。具体内容详见公司于 2023 年 5 月 18 日披露的《关于控股股东可交换公司债券进入换股期的提示性公告》（公告 编号：2023-036）。 万泽集团 2022 年面向专业投资者非公开发行可交换公司债券（第二期） （债券简称：22 泽 EB03、22 泽 EB04）以本公司股票为标的，于 2023 年 6 月 26 日进入换股期，换股期限为 2023 年 6 月 26 日起至 2025 年 ...